Loading...

PE anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_53-6dot7_PE_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 1_53-6dot7_PE_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 2_53-67_PE_CD8a_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD8a (clone 53-6.7) PE (solid line) or rat IgG2a, κ PE isotype control (dashed line).
Compare all formats See PE spectral data
Cat # Size Price Save
100707 50 µg ¥8,140
100708 200 µg ¥18,610
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  2. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  3. Lawson H, et al. 2021. Stem Cell Reports. 16:2784. PubMed
  4. Thomas R, et al. 2021. Immunology. 163:478. PubMed
  5. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  6. Zveik O, et al. 2022. Glia. 70:1191. PubMed
  7. Liu H, et al. 2022. Cancer Immunol Res. 10:1028. PubMed
  8. Silva Pereira S, et al. 2022. Elife. 11: . PubMed
  9. del Rio ML, et al. 2022. Front Immunol. 13:887348. PubMed
  10. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  11. Zheng D, et al. 2023. Bioact Mater. 22:567. PubMed
  12. Wang H, et al. 2022. J Nanobiotechnology. 20:513. PubMed
  13. He Y, et al. 2022. Front Immunol. 13:986202. PubMed
  14. Hao J, et al. 2022. Cell Rep. 41:111804. PubMed
  15. Shi C, et al. 2023. Nat Nanotechnol. 18:86. PubMed
  16. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  17. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  18. Kumpunya S, et al. 2023. Front Immunol. 13:1010764. PubMed
  19. Huseni MA, et al. 2023. Cell Rep Med. 4:100878. PubMed
  20. Glaubitz J, et al. 2023. Gut. :. PubMed
  21. Lin J, et al. 2023. Nat Commun. 14:224. PubMed
  22. Lu T, et al. 2023. Cancer Immunol Immunother. :. PubMed
  23. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  24. Pan C, et al. 2022. Cell Mol Immunol. 19:516. PubMed
  25. Kodali S, et al. 2022. J Immunol. 208:1085. PubMed
  26. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  27. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  28. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  29. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  30. He Y, et al. 2022. Adv Healthc Mater. 11:e2200905. PubMed
  31. Sugitani N, et al. 2022. Cell Rep. 40:111371. PubMed
  32. Shi X, et al. 2022. Proc Natl Acad Sci U S A. 119:e2208506119. PubMed
  33. Zhu C, et al. 2022. Chemotherapy. 67:211. PubMed
  34. Chen Y, et al. 2022. Am J Cancer Res. 12:5286. PubMed
  35. Sparbier CE, et al. 2023. Nat Cell Biol. 25:258. PubMed
  36. Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed
  37. Wang F, et al. 2023. Int J Mol Sci. 24:. PubMed
  38. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  39. Wang JX, et al. 2023. JCI Insight. 8:. PubMed
  40. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
  41. Dang YZ, et al. 2023. Neoplasma. 70:123. PubMed
  42. Tang C, et al. 2023. Nat Commun. 14:1493. PubMed
  43. Hao H, et al. 2023. Nat Biomed Eng. . PubMed
  44. Tao Q, et al. 2023. Microbiol Spectr. :e0522922. PubMed
  45. Fukuzaki Y, et al. 2023. iScience. 26:106340. PubMed
  46. del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed
  47. Liu H, et al. 2023. Breast Cancer Res. 25:43. PubMed
  48. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  49. Qin T, et al. 2023. Virol J. 20:75. PubMed
  50. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  51. Oh J, et al. 2023. Nat Commun. 14:3278. PubMed
  52. Ye S, et al. 2023. Front Oncol. 13:1202750. PubMed
  53. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  54. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  55. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  56. Wu SY, et al. 2022. Mol Cancer. 21:84. PubMed
  57. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  58. Manukian G, et al. 2021. Int J Radiat Oncol Biol Phys. 110:1341. PubMed
  59. Chen X, et al. 2009. Hum Immunol. 70:79. PubMed
  60. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  61. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  62. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  63. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  64. Hsu SPC, et al. 2020. J Neurooncol. 146:417. PubMed
  65. Qin Y, et al. 2021. Cell Rep. 37:109968. PubMed
  66. Sng XYX, et al. 2020. J Immunol. 204:3108. PubMed
  67. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  68. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  69. Hu HJ, et al. 2020. Cell Death Dis. 1.168055556. PubMed
  70. Yu K, et al. 2021. Cell Reports. 35(12):109273. PubMed
  71. He Y, et al. 2020. Sci Adv. 6:eaba7589. PubMed
  72. Zhao B, et al. 2020. Nat Commun. 11:908. PubMed
  73. van Erp EA, et al. 2019. Viruses. 0.811111111. PubMed
  74. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  75. Diao L, et al. 2022. iScience. 25:105511. PubMed
  76. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  77. Liu W, et al. 2021. Cell Mol Immunol. 18:2660. PubMed
  78. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  79. Wong J, et al. 2015. Elife. 3: 07839. PubMed
  80. Ibrahim M, et al. 2016. J Evid Based Complementary Altern Med. 21: 171 - 176. PubMed
  81. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  82. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  83. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  84. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  85. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  86. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  87. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  88. Tian X, et al. 2022. Front Immunol. 13:875236. PubMed
  89. N'guessan P, et al. 2011. Antioxid Redox Signal. 15:1693. PubMed
  90. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  91. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  92. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  93. Rana A, et al. 2020. Front Immunol. 11:536. PubMed
  94. Morabito KM, et al. 2017. Mucosal Immunol. 0.795138889. PubMed
  95. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  96. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  97. Uchida A, et al. 2021. J Inflamm Res. 14:3089. PubMed
  98. Jia L, et al. 2022. Front Immunol. 13:897879. PubMed
  99. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  100. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  101. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  102. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  103. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  104. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  105. Lo W, Allen D 2012. Nat Immunol. 13:880. PubMed
  106. Perry JSA, et al. 2018. Immunity. 48:923. PubMed
  107. Li J, et al. 2019. JCI Insight. 5. PubMed
  108. Meyer LK, et al. 2019. J Clin Invest. 130:863. PubMed
  109. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  110. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  111. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  112. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  113. Dang Y, et al. 2022. Cancer Cell Int. 22:88. PubMed
  114. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  115. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  116. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  117. Zhang Y, et al. 2015. PLoS Pathog. 11: e1005167. PubMed
  118. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  119. Levine LS, et al. 2021. Immunity. 54(4):829-844.e5. PubMed
  120. Frazier T, et al. 2018. Adipocyte. 0.41875. PubMed
  121. Naing A et al. 2019. Cell reports. 26(5):1242-1257 . PubMed
  122. Yang R, et al. 2022. Front Pharmacol. 13:774440. PubMed
  123. Hu G, et al. 2022. Cell Death Dis. 13:640. PubMed
  124. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  125. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  126. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  127. Lee CG, et al. 2019. JCI Insight. 4:5. PubMed
  128. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  129. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  130. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  131. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  132. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  133. Sá da Bandeira D, et al. 2022. Cell Rep. 40:111114. PubMed
  134. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  135. Yang H, et al. 2022. Nutrients. 14:. PubMed
  136. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  137. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  138. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  139. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  140. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  141. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  142. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  143. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  144. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  145. James OJ, et al. 2021. Nat Commun. 12:4290. PubMed
  146. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  147. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  148. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  149. Guo C, et al. 2017. Methods Mol Biol. 1709:345. PubMed
  150. Burr ML, et al. 2019. Cancer Cell. 36:385. PubMed
  151. Loh Z, et al. 2020. PLOS Pathogens. 16(7):e1008651. PubMed
  152. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  153. Cho K, et al. 2021. iScience. 24:103117. PubMed
  154. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  155. Zhao X, et al. 2013. Int Immunopharmacol. 17:793. PubMed
  156. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  157. Schuldt N, et al. 2015. PLoS One. 10: 0145762. PubMed
  158. Thomas AM, et al. 2020. Journal of Cellular Physiology. 235(6):5120-5129.. PubMed
  159. Manrique-Rincón A, et al. 2017. Front Immunol. 10.3389/fimmu.2017.01150. PubMed
  160. Chan WF, et al. 2022. Nat Commun. 13:5582. PubMed
  161. Moutuou MM, et al. 2020. Methods Mol Biol. 2111:267. PubMed
  162. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  163. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  164. Lin J, et al. 2021. Nat Commun. 12:5321. PubMed
  165. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  166. Monaghan KL, et al. 2020. J Vis Exp. . PubMed
  167. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  168. Echevarría-Vargas IM, et al. 2018. EMBO Mol Med. 10:e8446. PubMed
  169. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  170. Watson MJ, et al. 2021. Nature. 591:645. PubMed
  171. Wu S, et al. 2021. Nat Cancer. 2:189. PubMed
  172. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  173. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  174. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  175. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  176. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  177. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  178. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  179. Rodriguez-Sosa M, et al. 2004. Infect Immun. 72:4552. PubMed
  180. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  181. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  182. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  183. Zhang J, et al. 2018. Nature. 553:91. PubMed
  184. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  185. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
  186. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  187. Shen DD, et al. 2022. Mol Cancer. 21:75. PubMed
  188. Zhu J, et al. 2021. Cancer Cell Int. 21:529. PubMed
  189. Baranwal G, et al. 2021. Physiol Rep. 9:e15094. PubMed
  190. Bristow CL, et al. 2021. Front Oncol. 11:739080. PubMed
  191. Li J, et al. 2020. Development. :. PubMed
  192. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  193. Li J, et al. 2020. FASEB J. 34:3091. PubMed
  194. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  195. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  196. Eisemann T, et al. 2019. Front Oncol. 9:187. PubMed
  197. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  198. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  199. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  200. Tsai SJ, et al. 2021. J Biol Chem. 297:101266. PubMed
  201. Pai M, et al. 2016. JPEN J Parenter Enteral Nutr. 40: 383 - 391. PubMed
  202. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  203. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  204. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  205. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  206. Koide S, et al. 2022. iScience. 25:103603. PubMed
  207. Kline JM, et al. 2021. J Biol Chem. :100373. PubMed
  208. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  209. Ene CI, et al. 2020. Neuro Oncol. 639:22. PubMed
  210. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  211. Xu C, et al. 2020. Immunity. 53(2):417-428.e4. PubMed
  212. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  213. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  214. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
  215. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  216. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  217. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  218. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  219. Wu G, et al. 2021. Nat Cancer. 2:1170. PubMed
  220. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  221. Schnoegl D, et al. 2022. Front Immunol. 13:909270. PubMed
  222. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  223. Wong L, et al. 2013. J Biol Chem. 288:35170. PubMed
  224. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  225. Wu Y, et al. 2015. J Immunol. 195: 2612-2623. PubMed
  226. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  227. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  228. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  229. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  230. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  231. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  232. Chavez JS, et al. 2022. Cells. 11:. PubMed
  233. Wang X, et al. 2022. Elife. 11:. PubMed
  234. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  235. Wang X, et al. 2021. Theranostics. 11:209. PubMed
  236. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  237. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  238. LeBlanc P, et al. 2014. J Biol Chem. 289:7777. PubMed
  239. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  240. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  241. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  242. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  243. Gawish R, et al. 2022. Elife. 11:. PubMed
  244. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  245. Kang YA, et al. 2020. J Exp Med. 217:00:00. PubMed
  246. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  247. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  248. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  249. Zeng A, et al. 2020. Oncol Rep. . PubMed
  250. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
  251. Lee YT, et al. 2018. PLoS One. 13:e0190868. PubMed
  252. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  253. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  254. Pastor Arroyo EM, et al. 2022. Clin Sci (Lond). 136:557. PubMed
  255. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  256. Lv K, et al. 2021. Cell Stem Cell. 28(7):1275-1290.e9. PubMed
  257. Yang E, et al. 2015. Acta Biochim Biophys Sin. 47: 588-596. PubMed
RRID
AB_312747 (BioLegend Cat. No. 100707)
AB_312747 (BioLegend Cat. No. 100708)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account